# Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

> **NCT04981119** · — · RECRUITING · sponsor: **A2 Biotherapeutics Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Colorectal Cancer
- Non Small Cell Lung Cancer
- Pancreatic Cancer
- CRC
- NSCLC
- Pancreas Cancer
- Mesothelioma
- Ovarian Cancer
- Ovarian Neoplasms
- Ovarian Carcinoma
- Mesothelioma, Malignant
- Mesothelioma; Lung
- Cancer
- Triple Negative Breast Cancer (TNBC)
- Renal Cell Carcinoma (Kidney Cancer)
- Head and Neck Squamous Cell Carcinoma HNSCC

## Interventions

- **OTHER:** Apheresis
- **DIAGNOSTIC_TEST:** Next Generation Sequencing (NGS)
- **DIAGNOSTIC_TEST:** Long Range NGS HLA typing

## Key facts

- **NCT ID:** NCT04981119
- **Lead sponsor:** A2 Biotherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-29
- **Primary completion:** 2028-12
- **Final completion:** 2029-04
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04981119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04981119, "Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04981119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*